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Leveraging brain cortex-derived molecular
data to elucidate epigenetic and
transcriptomic drivers of complex traits and
disease
Charlie Hatcher 1, Caroline L. Relton 1, Tom R. Gaunt 1 and Tom G. Richardson 1
Abstract
Integrative approaches that harness large-scale molecular datasets can help develop mechanistic insight into ﬁndings
from genome-wide association studies (GWAS). We have performed extensive analyses to uncover transcriptional and
epigenetic processes which may play a role in complex trait variation. This was undertaken by applying Bayesian
multiple-trait colocalization systematically across the genome to identify genetic variants responsible for inﬂuencing
intermediate molecular phenotypes as well as complex traits. In this analysis, we leveraged high-dimensional
quantitative trait loci data derived from the prefrontal cortex tissue (concerning gene expression, DNA methylation
and histone acetylation) and GWAS ﬁndings for ﬁve complex traits (Neuroticism, Schizophrenia, Educational
Attainment, Insomnia and Alzheimer’s disease). There was evidence of colocalization for 118 associations, suggesting
that the same underlying genetic variant inﬂuenced both nearby gene expression as well as complex trait variation. Of
these, 73 associations provided evidence that the genetic variant also inﬂuenced proximal DNA methylation and/or
histone acetylation. These ﬁndings support previous evidence at loci where epigenetic mechanisms may putatively
mediate effects of genetic variants on traits, such as KLC1 and schizophrenia. We also uncovered evidence implicating
novel loci in disease susceptibility, including genes expressed predominantly in the brain tissue, such as MDGA1,
KIRREL3 and SLC12A5. An inverse relationship between DNA methylation and gene expression was observed more
than can be accounted for by chance, supporting previous ﬁndings implicating DNA methylation as a transcriptional
repressor. Our study should prove valuable in helping future studies prioritize candidate genes and epigenetic
mechanisms for in-depth functional follow-up analyses.
Background
Genome-wide association studies (GWAS) have been
integral in identifying thousands of genetic variants
associated with complex traits and disease. The vast
majority of genetic variants identiﬁed in these studies
reside in intergenic or intronic regions of the genome and
are therefore predicted to exert their effects on complex
traits via changes in gene regulation1. Furthermore, there
is evidence which suggests that GWAS hits are often
located within regions of open chromatin and enhancers2.
Typically, genetic variants associated with molecular
phenotypes are enriched amongst single-nucleotide
polymorphisms (SNPs) that are linked to traits and dis-
eases3. Such variants are known as quantitative trait loci
(QTL) and can affect molecular phenotypes such as: gene
expression (eQTL), and epigenetic mechanisms including
DNA methylation (mQTL) and histone acetylation
(haQTL). DNA methylation and histone acetylation are
alterations that affect gene expression without altering the
DNA sequence. Several genetic variants have been iden-
tiﬁed that occur in the same genomic region and inﬂuence
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both gene expression and DNA methylation. In these
cases, it is possible that the eQTL and mQTL share a
common causal variant (CCV)4.
Several post-GWAS approaches exist to help function-
ally characterize non-coding variants5–7. In particular,
there has been an emphasis on integrating eQTL and
GWAS data together, which can be valuable in terms of
identifying the underlying genes responsible for associa-
tions detected by GWAS. Recently, similar endeavours
have extended the scope of their analysis to also evaluate
additional molecular phenotypes (e.g. mQTL and haQTL)
as well as gene expression8–11. A novel method in this
paradigm involves calculating approximate Bayes fac-
tors12 to assess the likelihood that the genetic variant
responsible for an association with a complex trait is also
responsible for inﬂuencing intermediate molecular phe-
notypes (i.e. the likelihood they share a CCV). This
multiple-trait colocalization (moloc) method has been
shown to help characterize GWAS loci and develop
mechanistic insight into the causal pathway from genetic
variant to complex trait13. Furthermore, inclusion of an
additional molecular trait into the analysis (e.g. complex
trait, gene expression and DNA methylation vs. complex
trait and gene expression alone) has been shown to
increase power and assist in identifying novel disease
susceptibility loci13.
The recent large inﬂux of tissue-speciﬁc molecular data
provides an unprecedented opportunity to assess the
functional relevance of GWAS hits. Recently, a resource
has become available that comprises QTL data derived
from the dorsolateral prefrontal cortex in up to 494 sub-
jects14. Brain xQTL Serve provides a list of SNPs asso-
ciated with gene expression, DNA methylation and/or
histone modiﬁcations speciﬁc to the same brain region14.
Whilst progress has been made in terms of identifying
genetic variants inﬂuencing neurological phenotypes and
diseases, not enough is known about the biological effects
of genetic risk factors. In this study, we have jointly ana-
lysed genetic variants identiﬁed across GWAS of ﬁve
complex traits and diseases alongside the variants listed in
the Brain xQTL Serve resource. In doing so, we aim to
identify CCVs for complex traits and gene expression, and
where possible, DNA methylation and histone acetylation.
We selected a range of neurological, psychiatric, person-
ality and behavioural traits (Neuroticism, Schizophrenia,
Educational Attainment, Insomnia and Alzheimer’s dis-
ease) with publicly available large GWAS summary sta-
tistics, where we believed QTL data speciﬁc to the brain
may be particularly biologically relevant. Uncovering
evidence that epigenetic factors reside on the causal
pathway along with gene expression can be extremely
valuable for disease prevention due to early diagnosis.
Additionally, the use of genetic evidence can be beneﬁcial
for identifying and selecting drug targets15.
Methods
Genome-wide association studies
We obtained summary statistics from ﬁve independent
GWAS for the following complex traits: Neuroticism (n
= 274,108)16, Schizophrenia (cases= 35,467, controls=
46,839)17, Educational Attainment (n= 293,723)18, Alz-
heimer’s disease (cases= 17,008, controls= 37,154)19 and
Insomnia (n= 336,965)16. Information on all GWAS
datasets can be found in Supplementary Table 1. Linkage
disequilibrium (LD) clumping was undertaken using
PLINK v1.920 with a reference panel consisting of Eur-
opean (CEU) individuals from phase 3 (version 5) of the
1000 genomes project21. This allowed us to identify the
top independent loci for each set of results based on the
conventional GWAS threshold (P < 5.0 × 10−08).
Brain tissue-derived QTL for three molecular phenotypes
All QTL data used in this study were obtained from the
Brain xQTL Serve resource14. Genotype data in this
resource was generated from 2093 individuals of Eur-
opean descent from the Religious Orders Study (ROS and
Memory and Aging Project study cohorts (http://www.
radc.rush.edu/). Gene expression (RNA-sequencing
(RNA-seq); n= 494), DNA methylation (450 K Illumina
array; n= 468) and histone modiﬁcation (H3K9Ac ChIP-
seq; n= 433) data were derived from the dorsolateral
prefrontal cortex of post-mortem samples. eQTL were
based on 13,484 expressed genes, mQTL on 420,103
methylation sites and haQTL on 26,384 acetylation
domains. eQTL and haQTL results were available for
variants within 1Mb of their corresponding probes,
whereas mQTL results were restricted to a 5 kb window14.
Gene-centric multiple-trait colocalization
We extracted effect estimates for all variants within
1Mb of the lead SNP (i.e. P < 5.0 × 10–08) for each
clumped region using results from each of the ﬁve GWAS.
P values for molecular QTL were then extracted for the
same set of SNPs using the Brain xQTL resource. Loci
residing within the major histocompatibility complex
region (chr6: 25−35Mb) were removed due to extensive
LD within this region, which may result in false-positive
ﬁndings. The moloc method was then used to assess the
likelihood that the variant at each region responsible for
variation in complex traits was also responsible for inﬂu-
encing the expression of a nearby gene (i.e. within a 1Mb
distance of the lead GWAS SNP). As demonstrated pre-
viously13, we simultaneously investigated whether variants
responsible for both gene expression and complex trait
variation may also inﬂuence proximal epigenetic traits in a
gene-centric manner. However, unlike previous work,
which evaluated three traits at a time, we have investigated
up to four traits in each analysis (i.e. complex trait, gene
expression, DNA methylation and histone acetylation).
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To achieve this, we used coordinates from Ensembl22 to
map CpG sites and histone peaks to genes using a 50-kb
window upstream and downstream of each gene. We then
ran moloc to assess all gene–CpG–histone combinations
within each region of interest. Summed posterior prob-
abilities were computed for all scenarios where GWAS
trait and gene expression colocalized. The reason for this
is because if epigenetic mechanisms are responsible for
mediating the effect of genetic variants on complex traits,
then we would expect gene expression to also reside on
this causal pathway. Therefore, 10 scenarios were con-
sidered of interest: GE, GE,M, GE,H, GE,M,H, GEM,
GEM,H, GEH, GEH,M, GEMH, where evidence of a
shared causal variants for GWAS complex traits is deﬁned
as ‘G', gene expression as ‘E’, DNA methylation as ‘M’ and
histone acetylation as ‘H’. The ‘,’ denotes a scenario where
there is a different causal variant for each molecular
phenotype. For example, GE,M would represent a situa-
tion where the same causal variant is shared between the
GWAS trait and gene expression, but a different causal
variant for DNA methylation.
As recommended by the authors of moloc13, a summed
posterior probability of association (PPA) ≥80% for these
10 scenarios was considered strong evidence that a
genetic variant was responsible for changes in both
molecular phenotype(s) and complex trait variation.
Therefore, a GEMH scenario with a posterior probability
≥80% would represent a case where there is evidence that
GWAS trait, gene expression, DNA methylation and
histone acetylation colocalize and share a causal variant.
When a gene–trait combination provided evidence of
colocalization with multiple CpG sites or histone peaks,
we only reported the association for the combination with
the highest PPA. This was to reduce the number of
ﬁndings detected due to co-methylation/probes within the
same histone peak that were measuring the same epige-
netic signatures.
Regions with fewer than 50 common SNPs (minor allele
frequency ≤5%) were not considered in the moloc analysis
in order to reduce the number of spurious ﬁndings. Prior
probabilities of 1 × 10−04, 1 × 10−06, 1 × 10−07 and 1 ×
10−08 were used in all analyses, which was also recom-
mended by the authors of moloc. Furthermore, we used
the option to adjust Bayes factors for overlapping samples
as this was the case for the xQTL datasets. Manhattan
plots to illustrate ﬁndings were subsequently generated
using code adapted from the ‘qqman’ package23.
Identifying potentially novel loci in disease susceptibility
We also applied our analytical pipeline as described
above to independent GWAS loci with P values between
the conventional threshold (P < 5.0 × 10−08) and P ≤ 1.0 ×
10−06. All parameters were the same as in the previous
analysis. We hypothesized that incorporating additional
evidence on molecular phenotypes could help to elucidate
potentially novel loci, which are likely to be identiﬁed as
sample sizes of future GWAS increase. Although the
observed effects of these loci on traits alone do not meet
the conventional GWAS threshold, we took evidence of
colocalization (again deﬁned as a combined PPA ≥80%) at
these loci as novel evidence implicating them in disease,
which can be used to prioritize them for future evaluation.
Functional informatics
Pathway analysis
For all scenarios where GWAS trait and gene expression
colocalize based on a combined PPA of ≥80%, we com-
piled a list of associated genes for each trait. Where
multiple genes at a region provided a PPA ≥80% for the
same GWAS SNP, we took forward the gene with the
highest PPA. Pathway analysis was then undertaken with a
gene list for each complex trait using Con-
sensusPathDB24. This was to investigate whether multiple
associated genes in our analysis reside along established
biological pathways more than we would expect by
chance.
Tissue-speciﬁc analysis
We also investigated whether any genes detected in our
analysis were predominantly expressed in the brain tissue
using three RNA-seq datasets: the Human Protein Atlas
(HPA)25, the Genotype-Tissue Expression project
(GTEx)26 and the Mouse ENCODE project27. We used
the ‘TissueEnrich’ R Package to identify evidence of
enrichment based on three deﬁnitions:25
● Tissue enriched: Genes with an expression level
≥1 TPM (transcripts per million) or FPKM
(fragments per kilobase of exon model per million
reads mapped) plus at least 5-fold higher expression
levels in a particular tissue when compared to all
other tissues.
● Group enriched: Genes with an expression level
≥1 TPM or FPKM plus at least 5-fold higher
expression levels in a group of 2–7 tissues when
compared to other tissues not considered to be
‘Tissue enriched’.
● Tissue enhanced: Genes with an expression level
≥1 TPM or FPKM plus at least 5-fold higher
expression levels in a particular tissue compared to
the average levels in all other tissues, and not
considered to be either ‘Tissue enriched’ or ‘Group
enriched’.
Evidence of enrichment under the ‘Tissue enriched’
deﬁnition therefore suggests that a gene is speciﬁcally
expressed in a single tissue type. This suggests that
associations between this gene and a complex trait may be
tissue speciﬁc (i.e. they would only be detected using data
derived from one speciﬁc tissue). Enrichment based on
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the ‘Group enriched’ deﬁnition suggests that associations
may be detected in a set of tissue types (i.e. 2–7 different
types), which are expressed at least 5-fold higher than all
other tissues considered. Evidence detected using the
‘Tissue enhanced’ deﬁnition suggests that this gene is
more ubiquitously expressed (in more than seven differ-
ent tissues), although expression in a speciﬁc tissue type is
considerably higher than the others (5-fold higher com-
pared to the average of all others). As such, genes detected
using this deﬁnition may be strongly dependent on using
data derived from one speciﬁc tissue, although associa-
tions may still be detected in other tissue types (i.e. they
are not ‘tissue speciﬁc’).
For each dataset, we were only interested in genes
predominantly expressed in the brain tissue, that is,
‘Cerebral Cortex’ in HPA, ‘Brain’ in GTEx and ‘Cere-
bellum’, ‘Cortex’ or ‘E14.5 Brain’ in the Mouse ENCODE
project. Heatmaps to illustrate enrichment across all
possible tissues from these datasets were generated using
the ‘ggplot’ R package’28.
Orienting directions of effect between molecular traits and
regulatory region annotation
We oriented the direction of effect between transcrip-
tional and epigenetic traits for detected associations:
ﬁrstly, between gene expression and DNA methylation
and then between gene expression and histone acetyla-
tion. For associations with evidence of colocalization
between the two traits being assessed, we evaluated
whether the lead SNP was correlated with molecular traits
in the same direction using coefﬁcients from the xQTL
resource. We applied the hypergeometric test to investi-
gate whether there was an enrichment of a particular
direction of effect between molecular traits more than we
would expect by chance. Background expectations were
calibrated using randomly selected lead SNPs across the
genome that were associated with both proximal gene
expression and DNA methylation (P < 1.0 × 10−04). Per-
mutation testing was applied for 10,000 iterations by
sampling the same number of SNPs being evaluated.
Lastly, we obtained regulatory data from the Roadmap
Epigenetics Project29 from 10 different types of the brain
tissue. We used BEDtools30 to evaluate whether lead
SNPs, CpG sites and histone peaks with evidence of
colocalization from our study reside within promoters,
enhancers and histone marks using these datasets. All
analyses in this study were undertaken using R (version
3.3.1).
Results
Colocalization between gene expression, DNA methylation
and histone acetylation at risk loci for ﬁve complex traits
We applied the moloc method at loci with a trait-
associated SNP (P < 5.0 × 10−08) using ﬁndings from ﬁve
large-scale GWAS16–19 and molecular datasets (eQTL,
mQTL and haQTL) derived from the brain tissue14.
Across the ﬁve complex traits, we identiﬁed a total of 66
colocalization associations with GWAS loci and gene
expression (Supplementary Tables 2–6). Of these, 40
provided evidence of colocalization with an epigenetic
trait also. Altogether, four genetic loci colocalized with a
complex trait and all three of the molecular phenotypes
(gene expression, DNA methylation and histone acetyla-
tion). Figure 1 illustrates these associations for neuroti-
cism and insomnia, whereas plots for the remaining traits
can be located in Supplementary Figure 1.
We identiﬁed evidence of colocalization between com-
plex and molecular traits at loci previously reported as
well as novel ﬁndings. For example, we were able to
replicate ﬁndings reporting that the expression of KLC1
colocalizes with schizophrenia risk and DNA methyla-
tion13 (combined PPA= 97.9%). There were several other
loci associated with schizophrenia that have been pre-
viously reported to colocalize with molecular traits (such
as CNNM2 and PRMT713), as well as a several other genes
where epigenetic mechanisms have not been previously
detected to play a role in schizophrenia risk (such as
TSNARE1 and ADOPT1) (Supplementary Table 3).
There were also novel associations with molecular
phenotypes amongst the other complex traits. For
instance, we uncovered evidence suggesting that neuro-
ticism, gene expression and DNA methylation shared a
CCV at the PAFAH1B1 locus (combined PPA= 89.9%).
Figure 2a illustrates the overlapping distributions of
effects on each of these traits for variants at this region.
We also observed evidence of colocalization for several
genes at the APOE locus that were associated with Alz-
heimer’s disease. This included TOMM40, where results
suggested that there was also evidence of colocalization
with DNA methylation (combined PPA= 99.3%). How-
ever, given the extensive LD at this region, ﬁndings should
be interpreted with caution31.
Elucidating novel genes that may inﬂuence complex traits
We also applied our analytical pipeline to uncover
potentially novel loci using a less stringent threshold (P ≤
1.0 × 10−06). In this analysis, we identiﬁed 52 loci where
complex traits and gene expression share a CCV, of which
33 provided evidence that these variants may also inﬂu-
ence epigenetic traits (Fig. 1; Supplementary Figure 1).
Our incentive for undertaking this analysis was that
GWAS analyses may not identify evidence of association
using observed effects on complex traits alone. However,
by integrating evidence that SNPs at these loci also
inﬂuence molecular traits derived from a relevant tissue
type, we aimed to uncover novel loci in disease/trait
variation. Table 1 provides an overview of the number of
associations detected in our analysis.
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As an example of this, there was evidence that insomnia
risk and molecular traits share a CCV at the MDGA1
locus (combined PPA= 85.8%). However, the P value for
the lead SNP at this region did not reach conventional
GWAS thresholds (P= 7.7 × 10−07), suggesting that it
would have been potentially overlooked based on GWAS
evidence alone. As a validation of this ﬁnding, we found
that a recent GWAS of insomnia with a larger sample size
has found strong evidence of association at the MDGA1
locus, which survives conventional corrections (P= 4.0 ×
10−12)32. Figure 2b illustrates the overlapping distribution
of effects for genetic variants at MDGA1 on insomnia,
gene expression and DNA methylation.
We identiﬁed several other instances from our analysis
of loci with evidence of colocalization that have recently
been detected by GWAS, suggesting that our analytical
pipeline is valuable in terms of detecting novel ﬁndings.
For example, we found that expression of the CD40 and
SLC12A5 genes colocalize with risk of neuroticism. Both
genes have subsequently been identiﬁed as associated with
neuroticism at genome-wide signiﬁcance in a GWAS
meta-analysis33. Additionally, a recent large GWAS of
educational attainment identiﬁed several genetic variants
not previously found to reach genome-wide signiﬁcance
that we found to colocalize with molecular traits for the
following genes: DNAJB4, RERE, Corf73, DHX30, CD164
and GLCC1134.
Pathway and tissue-speciﬁc enrichment analysis
Pathway analysis was conducted using Con-
sensusPathDB24 to investigate whether any sets of genes
for each complex trait and disease reside along the same
biological pathway (Supplementary Table 12). Amongst
ﬁndings there was evidence that genes associated with
neuroticism in our analysis (SLC12A5, GNAI2 and
GNG12) reside on the GABAergic synapse pathway
(enrichment P= 2.34 × 10−4).
Our tissue-speciﬁc analysis indicated that various genes
with evidence of colocalization are predominantly
expressed in the brain. SLC12A5, KLC1 and KIRREL3 are
expressed speciﬁcally in the cerebral cortex using data
from the Human Protein Atlas25, whereas MDGA1 was
strongly expressed within the brain tissue using data from
the GTEx26 project. RAP1GAP2 was predominantly
expressed within the cortex tissue using ﬁndings from the
Mouse ENCODE project, amongst other loci are enriched
in the brain tissue based on this dataset (Supplementary
Table 13, Supplementary Figure 2).
Fig. 1 Manhattan plots highlighting loci with evidence of genetic colocalization. Manhattan plots for a neuroticism and b insomnia. Shared
causal variants with traits are represented for the following scenarios: gene expression (blue), gene expression and DNA methylation (red), gene
expression and histone acetylation (green) and gene expression, DNA methylation and histone acetylation (yellow). For example, in a GNG12 is
shown in yellow representing a case where there is a common causal variant (CCV) for neuroticism risk, expression of the gene GNG12, DNA
methylation and histone acetylation at this locus. PAFAH1B1 is shown in red, indicating that there is a CCV for neuroticism risk, expression of the
PAFAH1B1 gene and DNA methylation, but not for histone acetylation at this locus. The genome-wide signiﬁcance threshold (P < 5 × 10−08) is
illustrated in red
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Fig. 2 Regional association plots illustrating genetic colocalization at PAFAH1B1 and MDGA1. Regional association plots illustrating
colocalizations for the PAFAH1B1 gene (a) and MDGA1 gene (b) with neuroticism and insomnia, respectively. Effects for genetic variants on complex
traits (plotted in grey) and gene expression (blue) were available within a 1 Mb distance of the lead variant at each locus, whereas effects on DNA
methylation levels (red) were conﬁned to a 5kb distance
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We observed enrichment of an inverse relationship
between DNA methylation and gene expression across
loci, which provided evidence of colocalization for these
molecular traits (P= 1.98 × 10−03), supporting previous
evidence implicating DNA methylation as a transcrip-
tional repressor35 (Supplementary Table 14). This effect
appeared to be driven by CpG sites located near the
transcription start site of genes, as 11 of the 13 sites
located at these regions were inversely correlated with
gene expression (84.6%). Performing the same analysis
except with gene expression and histone acetylation
suggested that there was weak evidence of enrichment for
a directional relationship (P= 0.37). The regulatory
annotations within brain tissue datasets for lead SNPs and
CpG sites can be found in Supplementary Tables 15–17.
Discussion
In this study, we have conducted an integrative analysis
of GWAS and molecular QTL data to uncover mechan-
istic insight into the biological pathways underlying
complex traits. We identiﬁed 118 colocalization associa-
tions between complex traits and gene expression, with 73
of these associations additionally colocalizing with prox-
imal DNA methylation and/or histone acetylation in the
brain tissue. Out of the 118 associations, 52 were poten-
tially novel loci, which did not meet genome-wide sig-
niﬁcance corrections, but colocalized with molecular
traits. Notably, several of these potentially novel loci have
recently been validated by larger GWAS32–34, suggesting
that other ﬁndings in our study are likely to be identiﬁed
by GWAS as study sizes increase. Our ﬁndings should
help future studies prioritize candidate genes and putative
epigenetic mechanisms for functional follow-up analyses.
Validation of previous ﬁndings
Applying our analysis pipeline to GWAS loci associated
with complex traits and disease (i.e. P < 5 × 10−08) repli-
cated previous ﬁndings reported by functional studies. For
instance, our ﬁndings are consistent with an in-depth
evaluation of the KLC1 locus3. Variation at KLC1 pro-
vided strong evidence of colocalization in our study
(combined PPA= 97.9%), where the highest individual
posterior probability suggested that both gene expression
and DNA methylation may be involved along the causal
pathway to schizophrenia risk. This result also supports
ﬁndings from an epigenome-wide association study
implicating DNA methylation as potentially playing a role
in schizophrenia risk at this locus36. Furthermore, Hi-C
interactions have been identiﬁed at the promoter region
of KLC1 within the brain tissue, which further helps
validate the putative regulatory mechanism implicated by
our results37.
Amongst other established GWAS loci, there was evi-
dence suggesting that expression of the TOMM40 gene
and DNA methylation may play a role in Alzheimer’s
disease. An exploratory analysis has found that regulatory
element methylation levels in the TOMM40-APOE-
APOC2 gene region correlate with Alzheimer’s disease38.
Table 1 Number of associations with evidence of colocalization between complex and molecular traits
Complex trait Gene expression Gene expression and
DNAm
Gene expression and histone
acetylation
Gene expression and DNAm and
histone acetylation
Loci meeting GWAS threshold
Neuroticism 5 5 2 0
Schizophrenia 2 7 0 1
Education attainment 9 7 1 1
Alzheimer’s disease 6 3 1 0
Insomnia 4 9 1 2
Loci not meeting GWAS threshold
Neuroticism 5 2 2 1
Schizophrenia 9 6 4 0
Education attainment 3 3 3 0
Alzheimer’s disease 1 0 0 0
Insomnia 1 10 1 1
The total number of associations detected in our analysis with evidence of colocalization as assessed by a posterior probability of association ≥80% using multiple-
trait colocalization. Results are stratiﬁed based on the combination of molecular traits, which provided the strongest evidence that they share a causal variant with the
associated complex trait
GWAS genome-wide association studies, DNAm DNA methylation
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However, there is also evidence that, although SNPs at
this region are known to inﬂuence Alzheimer’s disease,
gene expression, and DNA methylation, they may be
attributed to different causal variants39. Moreover, there is
a complex LD structure at this region31, suggesting that
further analysis is required to fully understand the
mechanisms underlying this association.
In cases where gene expression was found to colocalize
with DNA methylation, we observed evidence of enrich-
ment for an inverse relationship between these molecular
phenotypes. Such inverse correlations support established
biology that DNA methylation plays a role in silencing
gene transcription40. However, recently there has been
conﬂicting reports concerning whether DNA methylation
on its own is sufﬁcient to lead to transcriptional repres-
sion of promoters35,41. Further analysis investigating the
epigenetic mechanisms identiﬁed by our study should
prove valuable in fully understanding the role of DNA
methylation in gene regulation.
Novel leads
We were also able to identify evidence of colocalization
at GWAS loci that have not been linked previously by
functional analyses or integrative studies harnessing
molecular traits. For instance, the underlying biology
explaining a GWAS association with neuroticism on
chromosome 17 (lead SNP= rs12938775) has yet to be
thoroughly evaluated. Our ﬁndings suggest that
PAFAH1B1 may be the likely causal gene at this locus, as
well as implicating the involvement of DNA methylation
along the causal pathway to neuroticism susceptibility as
well (combined PPA= 90.0%). PAFAH1B1 (also known as
LIS1) is involved in neuronal migration, the process by
which different classes of neurons are brought together so
that they can interact appropriately42. Functional evalua-
tions of how changes in DNA methylation may inﬂuence
neurological function at loci such as this may prove
valuable in understanding epigenetic contributions to
disease susceptibility. Moreover, doing so will help
improve the accuracy of early disease prognosis.
As well as helping characterize associations detected by
GWAS studies, we have also uncovered evidence for
many novel genes, which may inﬂuence complex trait
variation and therefore represent promising candidates
for future endeavours. The association with insomnia risk
at the MDGA1 locus is an example of this, particularly
given that it has recently been validated by a large-scale
GWAS32. Furthermore, our results may provide func-
tional insight into this association, by suggesting that
MDGA1 may be the responsible causal gene and that
DNA methylation may also play a role in disease risk at
this locus (combined PPA= 85.8%). Similar to
PAFAH1B1,MDGA1 has also been report to play a role in
neuronal migration43 and based on our tissue-speciﬁc
analysis is predominantly expressed in the brain tissue.
SLC12A5, associated with neuroticism in our analysis
(combined PPA= 99.0%), was amongst other promising
candidates which has yet to be discovered by GWAS. This
gene encodes the neuronal KCC2 channel, which plays a
crucial role in fast synaptic inhibition44. SLC12A5 was also
amongst the genes associated with neuroticism in our
analysis that resides along the GABAergic synapse path-
way (along with GNAI2 and GNG12). A recent study has
suggested that GABAegic neurons are causally associated
with risk of bipolar disorder45, a condition previously
linked with higher global measures of neuroticism46. The
association between KIRREL3 and neuroticism (combined
PPA= 92.2%) is another ﬁnding that has yet to be iden-
tiﬁed by GWAS, which warrants in-depth functional
evaluation. KIRREL3 regulates target-speciﬁc synapse
formation and has been previously linked with neurode-
velopmental disorders47. Our tissue-speciﬁc analysis
suggests that both SLC12A5 and KIRREL3 are pre-
dominantly expressed in the brain tissue.
Limitations of this study
In terms of limitations of this study, we recognize that
integration of GWAS results with QTL data is limited by
the sample sizes used to derive summary statistics, which
is particularly noteworthy for QTL data available in the
brain. It may be the case that replication in blood can
provide greater power due to the larger sample sizes
available. It has been shown that top cis-eQTL and mQTL
are highly correlated between blood and brain tissues48.
Future work could take advantage of this correlation and
the higher power in these blood datasets.
There is also evidence that the expression of certain genes
is both highly tissue and disease speciﬁc45. Recently, it has
been shown that both tissue-speciﬁc and tissue-shared
eQTL provide a substantial polygenic contribution to var-
ious complex traits27. Further investigation into the tissue
speciﬁcity of our results could be interesting since the
ROSMAP/Brain xQTL14 dataset comes speciﬁcally from
the dorsolateral prefrontal cortex region of the brain.
Analysis of effects in other regions of the brain may be
interesting to potentially identify disease-relevant regions.
We were also limited as the mQTL data was conﬁned to
5 kb windows affecting the coverage we could get within a
genomic region. Whilst the nature of this mQTL dataset
means we may have missed some true effects, it also means
we are unlikely to have identiﬁed false positives. It is also
worth noting that as the number of molecular studies
increases, so too does the likelihood of detecting incidental
QTL-GWAS overlaps3. Hence, developments concerning
robust methods in colocalization should prove to be
extremely valuable and important for future research.
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Conclusions
By integrating GWAS ﬁndings with data concerning
brain cortex-derived molecular phenotypes, we have
helped uncover putative epigenetic and transcriptomic
drivers of complex traits and disease. The polygenic nat-
ure of many psychiatric disorders has led to many chal-
lenges in terms of developing novel therapeutics49. Our
work has focused on the prioritization of GWAS hits to
uncover loci, which may be potential targets for ther-
apeutic intervention. Genetically informed targets have
been shown to have a higher success rate in clinical
development, with such targets being more likely to
progress to phase III trials15.
Animal studies are one possible approach to validate
and help translate the ﬁndings of our study. Knockout
studies, for example, could be used to investigate the
impact of whole gene loss-of-function on a particular
phenotype50. Furthermore, the loci we have uncovered
associated with changes in DNA methylation could be
validated by studies interested in using this epigenetic
marker to help predict later life disease events. Such
endeavours may help elucidate CpG sites that may be
valuable for disease prediction and patient stratiﬁcation.
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